We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert ... Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. Show more
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3...
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...
– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – Rapid onset and long duration...
Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.98 | 6.37605725439 | 15.37 | 17.25 | 15.18 | 178347 | 16.0840465 | CS |
4 | -1.05 | -6.03448275862 | 17.4 | 17.66 | 15 | 184346 | 16.07127401 | CS |
12 | 0.37 | 2.3153942428 | 15.98 | 24.59 | 15 | 149347 | 17.58259529 | CS |
26 | 0.37 | 2.3153942428 | 15.98 | 24.59 | 15 | 149347 | 17.58259529 | CS |
52 | 0.37 | 2.3153942428 | 15.98 | 24.59 | 15 | 149347 | 17.58259529 | CS |
156 | 0.37 | 2.3153942428 | 15.98 | 24.59 | 15 | 149347 | 17.58259529 | CS |
260 | 0.37 | 2.3153942428 | 15.98 | 24.59 | 15 | 149347 | 17.58259529 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions